What is Leviticus-Cardio?
Founded in 2008, Leviticus-Cardio operates at the intersection of advanced engineering and clinical cardiology. The company is primarily focused on enhancing the clinical outcomes for patients reliant on left ventricular assist devices (LVADs). By addressing the critical limitations of current mechanical circulatory support systems, Leviticus-Cardio aims to improve the quality of life and long-term survival rates for individuals suffering from impaired cardiac function. Their market position is defined by a commitment to bridging the gap between invasive surgical intervention and patient-centric, long-term cardiac support, positioning them as a pivotal player in the evolving landscape of heart failure treatment.
How much funding has Leviticus-Cardio raised?
Leviticus-Cardio has raised a total of $5.5M across 2 funding rounds:
Unspecified
$4M
Unspecified
$1.5M
Unspecified (2013): $4M, investors not publicly disclosed
Unspecified (2015): $1.5M, investors not publicly disclosed
Key Investors in Leviticus-Cardio
The Trendlines Group
A prominent investment group specializing in early-stage medical and agricultural technologies, known for fostering innovation within the Israeli life sciences ecosystem.
Israel Innovation Authority
A government-backed agency dedicated to supporting industrial research and development, providing critical non-dilutive financing to high-growth technology firms.
Cardiovascular Physician Consortium
A specialized group of clinical experts and surgeons providing both financial backing and essential medical insights to drive cardiovascular innovation.
What's next for Leviticus-Cardio?
With the recent influx of capital, Leviticus-Cardio is well-positioned to accelerate its research and development initiatives, focusing on the refinement of its core LVAD-related technologies. The company's strategic roadmap likely involves scaling clinical trials and navigating the rigorous approval processes required for broader market adoption. As the firm transitions from early-stage development to a more mature enterprise-level operation, the focus will shift toward commercialization strategies and the expansion of its intellectual property portfolio. Continued collaboration with cardiovascular specialists and institutional partners will be essential as the company seeks to establish its technology as a standard of care in the global cardiology market.
See full Leviticus-Cardio company page
